Trial Profile

A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 27 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niacin (Primary) ; Nivolumab (Primary) ; Padnarsertib (Primary)
Indications Colon cancer; Lung cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Sarcoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms PANAMA
Sponsors Karyopharm Therapeutics

Most Recent Events

22 Jun 2021 Status changed from recruiting to discontinued.
28 Jan 2021 Planned End Date changed from 1 May 2021 to 1 Aug 2021.
28 Jan 2021 Planned primary completion date changed from 1 May 2021 to 1 Aug 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com